• Oncotelic reported first patient dosed in Phase 1b trial of Sapu003, an investigational intravenous formulation of everolimus, in advanced mTOR-sensitive solid tumors.
• No efficacy results disclosed; study aims to assess safety and tolerability, characterize drug exposure, and gauge early signs of anti-tumor activity.
• Results were not presented; program previously featured at 2025 San Antonio Breast Cancer Symposium, with trial readouts pending.
• Trial uses weekly IV dosing in 4-week cycles, testing escalating dose levels, with combination therapy in one breast cancer cohort and monotherapy in a second cohort spanning multiple tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605131000PRIMZONEFULLFEED9719346) on May 13, 2026, and is solely responsible for the information contained therein.